Should Medicare and Medicaid eventually cover new weight loss drugs such as Ozempic and Wegovy? This week, Audacy took a look ...

Novo Nordisk will sell a less expensive one-month supply of Wegovy for patients who previously took compounded versions of ...

Wegovy belongs to a pricey class of drugs called GLP-1s (short for glucagon-like peptide-1 agonists) that have upended the ...

Cigna will cap out-of-pocket costs at $200 per month for patients using the weight-loss drugs Wegovy and Zepbound through an ...

Cigna’s pharmacy benefits unit Evernorth said the deal will bring prices down for employers and their workers.

As of late 2024, only 14 state Medicaid programs cover GLP-1 drugs like Wegovy, Saxenda, or Zepbound for the treatment of obesity. These states are: California, Connecticut, Indiana, Maryland, ...

With promising new obesity treatments in the pipeline, 24/7 Wall St. projects huge upside for Novo Nordisk stock through 2030 ...

Novo has a strong balance sheet and ended 2024 with about DKK 26 billion in cash and marketable securities and DKK 103 billion of debt (following the acquisition of Catalent manufacturing sites in ...